An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Recruiting

Phase 2

Roflumilast FoamAn Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Sponsor:

Derm Texas, PLLC

Code:

NCT07105254

Conditions

Non-segmental Vitiligo

Eligibility Criteria

Sex: All

Age: 2 - 18

Healthy Volunteers: Not accepted

Interventions

Roflumilast topical 0.3% foam

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-26. This information was provided to ClinicalTrials.gov by Derm Texas, PLLC on 2025-08-08.